October 2026

Hypertension with defective IGF1R-PI3K signalling may trigger atrial cardiomyopathy, atrial fibrillation, and stroke
 
Hypertension is the largest contributor to atrial fibrillation. Left atrial size and function are sensitive echocardiographic markers of individuals at increased risk. In this month’s paper you can learn more about how defect signalling in the insulin-like growth factor receptor phosphoinositide 3-kinase (IGF1R-PI3K) signalling pathway may play a key role in the association of hypertension with atrial dysfunction, atrial fibrillation and stroke.
 

September 2026 

Prevention of heart failure in women: an expert consensus statement on sex-specific risk factors

European Journal Of Heart Failure
3 Jul 2026

Although arterial hypertension is the most common cause of heart failure in women, it is important to assess female-specific risk factors in the prevention of heart failure. To update yourself on these aspects, I recommend reading the ESC expert consensus statement on Prevention of heart failure in women.

 

July 2026

Bridging the gap between hypertension guidelines and real-life practice: strategies and technological tools for improving long-term population blood pressure control

European Journal Of Preventive Cardiology
11 Dec 2025

The number of hypertensive patients worldwide is huge and constantly increasing.
Large differences in healthcare access are visible in different countries, and as such, proposing a specific algorithm suitable for every country is definitely not an easy task.
The paper summarises the barriers to the implementation of guideline-defined standards of care in high-, low-, and middle-income countries and considers some possible solutions to improve this situation. Present and future Strategies for diagnosis of elevated blood pressure and hypertension, monitoring its control, as well as therapy and follow-up are described.
Enjoy the lecture of the interesting review and use the practical tips in your practice for improving global hypertension control rates and reducing the burden of its complications.

June 2026

How to screen and diagnose hypertension

European Journal Of Preventive Cardiology
17 Oct 2025

A large proportion of individuals with arterial hypertension are unaware of their condition and therefore remain untreated. To overcome this problem, the 2024 European Society of Cardiology guidelines on elevated blood pressure and hypertension recommend that adults from age 18 have their blood pressure measured every third year, and from age 40 annual blood pressure measurement is recommended. When an elevated blood pressure is detected, the diagnosis of arterial hypertension requires confirmation by repeated office blood pressure measurement and out-of-office blood pressure. This month’s paper provides details about how you can more efficiently screen for and diagnose hypertension based on recommendations from major international hypertension guidelines.

May 2026

Selecting the optimal method for assessment of hypertension-mediated organ damage: a personalized approach

European Journal Of Preventive Cardiology
28 Jan 2026

The current ESC hypertension guidelines recommend looking for hypertension-mediated organ damage (HMOD) in the evaluation of patients with hypertension to identify high-risk individuals. Presence of HMOD is associated with a 2-3-fold higher risk of cardiovascular disease, even among patients with blood pressure in the elevated range (120-139/70-89 mmHg). In hypertension, basic assessment is recommended in all patients, while more advanced tests are recommended in selected patients. To help clinicians make informed decisions on what type of test to choose for HMOD assessment in the individual patient, we compared the recommendations of the most important recently issued hypertension guidelines and included our best advice.

April 2026 

Cuffless Blood Pressure Monitoring Devices: Technical Foundations and Clinical Implications: Scientific Statement of the European Society of Cardiology (ESC) Working Group on e-Cardiology, the ESC Council on Hypertension, and the European Association of Preventive Cardiology of the ESC

European Journal Of Heart Failure
25 Feb 2026

Cuffless blood pressure monitoring devices represent one of the most promising yet controversial innovations in contemporary hypertension care. By enabling continuous, unobtrusive BP assessment, they hold the potential to transform diagnosis and long-term management. However, as highlighted by Parati et al., current technologies remain limited by insufficient accuracy, lack of standardised validation, and reliance on indirect physiological surrogates. Despite growing commercial availability, these devices cannot yet be recommended for clinical decision-making, in line with international guidelines. The challenge ahead is clear: rigorous validation and demonstration of clinical benefit must precede widespread adoption, ensuring that technological progress translates into meaningful improvements in cardiovascular outcomes.